Travere Therapeutics is changing leadership. Eric Dube, Ph.D., who led the company’s turnaround and brought Filspari to market, is stepping down as CEO to focus on his health and family. Under Dube, Travere’s rare kidney disease drug Filspari won both accelerated and full FDA approval. Now, Bradley Campbell, a veteran in rare disease biotech, will take over.
In September 2026, Eric Dube sold approximately $25.4 million worth of Travere shares in transactions that occurred just days before the public announcement of his planned CEO departure.
“My own experiences with rare disease have also given me a profound appreciation for health, family and time,” Dube said. He is a two-time rare cancer survivor. In a LinkedIn post, he wrote about the toll of constant advocacy and said, “I’ve decided it’s time for me to listen more closely to that lesson.”
The board picked Campbell, who led Amicus Therapeutics through its $4.8 billion sale to BioMarin, to become CEO on December 1, 2026. Dube will stay on as executive advisor until February 2027 to help with the handover. Board chairman Gary Lyons pointed to Campbell’s mix of scientific, commercial, and operational experience as the main reason for his selection. Lyons said Campbell has shown he can drive growth and move clinical programs forward. According to an official company press release, Campbell will also join Travere's board of directors on December 1, 2026.
Travere Therapeutics confirmed that Eric Dube will remain CEO until December 1, 2026, after which he will serve as executive advisor through February 15, 2027, to ensure an orderly leadership transition.
“I see an exciting opportunity to build on that momentum, reach more people living with rare disease and continue creating meaningful value for all stakeholders,” Campbell said. He plans to build on Travere’s culture and recent wins.
Dube leaves behind a company transformed by the launch and growth of Filspari. Now, Travere faces the challenge of keeping up its pace under Campbell. The company’s future will depend on how well it can deliver on both regulatory and commercial goals in a crowded rare disease market. This leadership change is a calculated move to keep Travere’s momentum going at a time when timing and execution matter most.
Markets reacted quickly to the news. Travere shares fell after the CEO transition was announced, according to MarketWatch coverage on September 21, 2026.
